CRANBURY, N.J.--(BUSINESS WIRE)--VaxInnate Corporation announced today that it has commenced its first Phase 1 clinical trial, testing its M2e universal influenza vaccine. The universal vaccine is designed to target the M2 ectodomain (M2e) portion of the flu virus, which is inherent regardless of virus strain. The study will provide investigators with important information on the vaccine’s safety and immunogenicity, a patient’s ability to generate an immune response. The study will also provide important information on VaxInnate’s toll like receptor (TLR) technology utilizing flagellin, which helps to strengthen the body’s immune response by triggering both of the major arms of immune defense – innate (non-specific) and adaptive (specific).
